SARS-CoV-2: Targeted managements and vaccine development.
Angiotensin-Converting Enzyme 2
/ physiology
Antiviral Agents
/ isolation & purification
COVID-19
/ immunology
COVID-19 Vaccines
/ therapeutic use
Drug Development
/ methods
Genome, Viral
/ physiology
Humans
Molecular Targeted Therapy
/ methods
SARS-CoV-2
/ drug effects
Viral Vaccines
/ therapeutic use
COVID-19 Drug Treatment
ACE2
COVID-19
Chemokines
Cytokines
Immunity
Spike protein
Vaccines
Journal
Cytokine & growth factor reviews
ISSN: 1879-0305
Titre abrégé: Cytokine Growth Factor Rev
Pays: England
ID NLM: 9612306
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
13
11
2020
revised:
23
11
2020
accepted:
25
11
2020
pubmed:
10
12
2020
medline:
21
4
2021
entrez:
9
12
2020
Statut:
ppublish
Résumé
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in diverse outcomes. The symptoms appear to be more severe in males older than 65 and people with underlying health conditions; approximately one in five individuals could be at risk worldwide. The virus's sequence was rapidly established days after the first cases were reported and identified an RNA virus from the Coronaviridae family closely related to a Betacoronavirus virus found in bats in China. SARS-CoV-2 is the seventh coronavirus known to infect humans, and with the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), the only ones to cause severe diseases. Lessons from these two previous outbreaks guided the identification of critical therapeutic targets such as the spike viral proteins promoting the virus's cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor expressed on the surface of multiple types of eukaryotic cells. Although several therapeutic agents are currently evaluated, none seems to provide a clear path for a cure. Also, various types of vaccines are developed in record time to address the urgency of efficient SARS-CoV-2 prevention. Currently, 58 vaccines are evaluated in clinical trials, including 11 in phase III, and 3 of them reported efficacy above 90 %. The results so far from the clinical trials suggest the availability of multiple effective vaccines within months.
Identifiants
pubmed: 33293238
pii: S1359-6101(20)30227-6
doi: 10.1016/j.cytogfr.2020.11.001
pmc: PMC7706592
pii:
doi:
Substances chimiques
Antiviral Agents
0
COVID-19 Vaccines
0
Viral Vaccines
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-29Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Adv Biomark Sci Technol. 2020;2:1-23
pubmed: 33511330
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
J Virol. 2004 Jun;78(11):5642-50
pubmed: 15140961
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Mol Ther. 2019 Apr 10;27(4):757-772
pubmed: 30803823
Int J Antimicrob Agents. 2020 Aug;56(2):105998
pubmed: 32360231
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
Circ Res. 2005 Oct 28;97(9):946-53
pubmed: 16179584
JAMA. 2020 Sep 8;324(10):951-960
pubmed: 32789505
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):335-337
pubmed: 32087098
Sci Adv. 2020 Nov 6;6(45):
pubmed: 33036961
Exp Mol Pathol. 2007 Dec;83(3):283-95
pubmed: 17945211
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Biochem J. 2020 Mar 13;477(5):1009-1019
pubmed: 32083638
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
Science. 2003 Oct 10;302(5643):276-8
pubmed: 12958366
Lancet. 2020 Mar 28;395(10229):1039-1046
pubmed: 32192580
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
J Infect Dis. 2020 Apr 27;221(10):1688-1698
pubmed: 31822885
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Thromb Res. 2020 Sep;193:98
pubmed: 32534328
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Antivir Ther. 2007;12(7):1107-13
pubmed: 18018769
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Front Pharmacol. 2020 Aug 19;11:1258
pubmed: 32973505
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
FASEB J. 2020 May;34(5):6027-6037
pubmed: 32350928
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
Med. 2020 Dec 18;1(1):105-113.e4
pubmed: 32838353
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Nat Rev Immunol. 2020 Aug;20(8):453-454
pubmed: 32546853
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
PLoS Biol. 2008 Sep 16;6(9):e226
pubmed: 18798692
Circ Res. 2020 Sep 17;:
pubmed: 32938299
N Engl J Med. 2020 May 21;382(21):e68
pubmed: 32369286
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
N Engl J Med. 2020 Jun 18;382(25):2469-2471
pubmed: 32558474
Protein J. 2020 Jun;39(3):198-216
pubmed: 32447571
J Virol. 2000 Apr;74(7):3399-403
pubmed: 10708457
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53
pubmed: 15496474
Cell. 1989 May 19;57(4):537-47
pubmed: 2720781
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93
pubmed: 15897467
Rheumatol Ther. 2018 Jun;5(1):21-42
pubmed: 29502236
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
J Cell Mol Med. 2020 Jul;24(13):7670-7674
pubmed: 32512633
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93
pubmed: 17556654
Science. 1990 Mar 23;247(4949 Pt 1):1465-8
pubmed: 1690918
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):75-78
pubmed: 32500858
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
J Virol. 2010 May;84(9):4183-93
pubmed: 20147391
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
J Virol. 2004 Nov;78(21):12090-5
pubmed: 15479853
JAMA. 2020 Jun 23;323(24):2455-2457
pubmed: 32421150
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23652-23662
pubmed: 32868447
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32427582
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Nature. 2011 Nov 09;480(7378):534-7
pubmed: 22080952
Antiviral Res. 2014 Mar;103:39-50
pubmed: 24418573
J Virol. 2009 Apr;83(7):3039-48
pubmed: 19004938
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Lancet Respir Med. 2020 Nov;8(11):1154-1158
pubmed: 33131609
Nat Prod Bioprospect. 2020 Aug;10(4):171-186
pubmed: 32529545
Cell Discov. 2020 May 2;6:28
pubmed: 32373347
Vaccine. 2020 Nov 3;38(47):7533-7541
pubmed: 33039209
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445702
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6360-5
pubmed: 11353871
Nature. 2020 Jun;582(7813):469
pubmed: 32546811
Res Pract Thromb Haemost. 2020 Jun 12;4(4):524-531
pubmed: 32542213
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
J Thromb Thrombolysis. 2020 Oct;50(3):479-483
pubmed: 32519164
Transfus Apher Sci. 2020 Oct;59(5):102850
pubmed: 32540345
Cell Rep. 2020 Sep 22;32(12):108185
pubmed: 32941788
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492
pubmed: 32331982
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
JAMA. 1999 Jul 14;282(2):137-44
pubmed: 10411194
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Gene Ther. 2004 Apr;11(8):711-21
pubmed: 14724672
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Virol J. 2020 Sep 24;17(1):141
pubmed: 32972430
Front Cell Infect Microbiol. 2019 Jul 03;9:241
pubmed: 31334134
J Virol. 2011 Jan;85(2):873-82
pubmed: 21068237
J Virol. 2013 Dec;87(23):12552-61
pubmed: 24027332
Turk J Med Sci. 2020 Apr 15;50(SI-1):611-619
pubmed: 32293834
Trends Plant Sci. 2020 Jul;25(7):635-643
pubmed: 32371057
Clin Infect Dis. 2021 Aug 2;73(3):531-534
pubmed: 32770240
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632
pubmed: 32299202
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
J Virol. 2020 Jul 1;94(14):
pubmed: 32357959
Hum Vaccin Immunother. 2016 Apr 2;12(4):1070-9
pubmed: 26752023
J Immunol. 2020 Jul 15;205(2):307-312
pubmed: 32493814
Front Public Health. 2015 Nov 26;3:269
pubmed: 26636066
Nat Rev Immunol. 2020 Nov;20(11):650
pubmed: 32989290
Signal Transduct Target Ther. 2020 Dec 4;5(1):283
pubmed: 33277466
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Mol Immunol. 2009 Jan;46(3):355-61
pubmed: 19041135
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Stem Cell Rev Rep. 2020 Jun;16(3):434-440
pubmed: 32307653
Blood. 1988 Jan;71(1):1-8
pubmed: 3275472
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Natl Sci Rev. 2020 Jun;7(6):998-1002
pubmed: 34676125
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
JAMA. 2020 Oct 6;324(13):1298-1306
pubmed: 32876689
N Engl J Med. 2014 Jun 26;370(26):2499-505
pubmed: 24896817
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
pubmed: 18063357
Clin Pract. 2020 May 28;10(2):1271
pubmed: 32509258
Science. 2020 Jun 26;368(6498):1422-1424
pubmed: 32461212
Mayo Clin Proc. 2020 Oct;95(10):2172-2188
pubmed: 33012348
Annu Rev Med. 1989;40:431-46
pubmed: 2658759
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Front Immunol. 2020 Sep 02;11:2132
pubmed: 32983172
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32312781
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Cell. 2020 Apr 16;181(2):223-227
pubmed: 32220310
Nat Rev Immunol. 2020 Jul;20(7):427-441
pubmed: 32015473
Nat Rev Immunol. 2016 Jul;16(7):407-20
pubmed: 27291964
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Front Immunol. 2020 Sep 30;11:583077
pubmed: 33101309
Vaccine. 2008 Nov 25;26(50):6338-43
pubmed: 18824060
Antiviral Res. 2013 Nov;100(2):407-19
pubmed: 23994190
J Virol. 2013 May;87(10):5502-11
pubmed: 23468491
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Life Sci Alliance. 2020 Jul 23;3(9):
pubmed: 32703818
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326
J Med Virol. 2020 Nov;92(11):2693-2701
pubmed: 32497323
Trends Pharmacol Sci. 2020 Nov;41(11):815-829
pubmed: 32829936
Clin Pharmacokinet. 2013 Sep;52(9):783-92
pubmed: 23681967